Abstract:Pre‐eclampsia and fetal growth restriction (FGR) cause high levels of morbidity and mortality in pregnancy, despite significant pharmaceutical and technological advances in other disease areas. This article reviews the reasons why effective drug treatments are lacking and describes how nanomedicines and targeted drug delivery approaches may provide the solution to the current drug drought in obstetrics. Image created with BioRender.com Pre‐eclampsia and fetal growth restriction (FGR) continue to cause unacceptably high levels of morbidity and mortality, despite significant pharmaceutical and technological advances in other disease areas. The recent pandemic has also impacted obstetric care, as COVID‐19 infection increases the risk of poor pregnancy outcomes. This review explores the reasons why it lacks effective drug treatments for the placental dysfunction that underlies many common obstetric conditions and describes how nanomedicines and targeted drug delivery approaches may provide the solution to the current drug drought. The ever‐increasing range of biocompatible nanoparticle formulations available is now making it possible to selectively deliver drugs to uterine and placental tissues and dramatically limit fetal drug transfer. Formulations that are refractory to placental uptake offer the possibility of retaining drugs within the maternal circulation, allowing pregnant individuals to take medicines previously considered too harmful to the developing baby. Liposomes, ionizable lipid nanoparticles, polymeric nanoparticles, and adenoviral vectors have all been used to create efficacious drug delivery systems for use in pregnancy, although each approach offers distinct advantages and limitations. It is imperative that recent advances continue to be built upon and that there is an overdue investment of intellectual and financial capital in this field.

Lipid-delivery system could treat life-threatening pregnancy complication

Emerging Pharmacologic Interventions for Pre-Eclampsia Treatment

Size-dependent Placental Retention Effect of Liposomes in ICR Pregnant Mice: Potential Superiority in Placenta-Derived Disease Therapy

Study on lipid nanomicelles targeting placenta for the treatment of preeclampsia

Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia

Trophoblast-Targeted Liposomes for Placenta-Specific Drug Delivery

Advance in Placenta Drug Delivery: Concern for Placenta-Originated Disease Therapy.

Placental Drug Delivery to Treat Pre‐Eclampsia and Fetal Growth Restriction

Therapeutic effect of E-Lip-siRNA-sFlt1 on pre-eclampsia: targeted gene silencing and improved pregnancy outcomes

Efficient Sirna Transfer to Knockdown a Placenta Specific Lncrna Using RGD-modified Nano-Liposome: A New Preeclampsia-Like Mouse Model.

Lipid nanoparticle structure and delivery route during pregnancy dictate mRNA potency, immunogenicity, and maternal and fetal outcomes

Liposome-Encapsulated Anti-inflammatory Proteins for Targeted Delivery to the Placenta to Treat Fetal Growth Restriction

Targeted Delivery of Epidermal Growth Factor to the Human Placenta to Treat Fetal Growth Restriction

Placental Therapeutic Targets and Nanodelivery Systems

Tracing the Lipid Fingerprints of Preeclampsia

Gene therapy in preeclampsia: the dawn of a new era

Placenta-targeted Treatment Strategies for Preeclampsia and Fetal Growth Restriction: An Opportunity and Major Challenge

Vitamin B-3 Nicotinamide: A Promising Candidate For Treating Preeclampsia And Improving Fetal Growth

EGFR-targeted ionizable lipid nanoparticles enhance in vivo mRNA delivery to the placenta

Treatment of Lipoxin A4 and Its Analogue on Low-Dose Endotoxin Induced Preeclampsia in Rat and Possible Mechanisms

Functionally Integrating Nanoparticles Alleviate Deep Vein Thrombosis in Pregnancy and Rescue Intrauterine Growth Restriction